Rhodococcus equi (Prescottella equi) vaccines; the future of vaccine development.

This research article focuses on the ongoing development of vaccines for Rhodococcus equi (also known as Prescottella equi), with a particular interest in newer bacterial vector vaccines. Despite past attempts with various types of vaccines, none so far have provided adequate protection, leading researchers to explore alternative methods.

Overview of Rhodococcus equi Vaccines

• The research concentrates on Rhodococcus equi (Prescottella equi), a bacterium that poses a significant threat to the horse breeding industry, as it can cause disease in foals.
• For many years, the research in this field has endeavoured to prevent the spread of R. equi through vaccination. The horse breeding industry has also been supportive of these research efforts.

Challenges in Vaccine Development

• The development of a safe, efficient, and cost-effective vaccine for R. equi has proven challenging.
• More traditional forms of vaccines, those that are live, killed, or attenuated (via physical or chemical means), have failed to provide the desired results.
• Moreover, even more modern, molecular-based vaccines, such as the DNA plasmid, genetically attenuated, and subunit vaccines, have not offered satisfactory protection for foals against the disease.

Promise of Bacterial Vector Vaccines

• The research points to a newer range of vaccines, bacterial vector vaccines, which seem to hold significant promise in the fight against R. equi, particularly noting positive results from the mouse model.

Looking at Alternative Methods

• Given the challenges faced and the inadequate performance of current vaccine types, the research also explores potentially viable alternative methods that can be utilised in vaccine development for R. equi.
• The article highlights various promising research findings in R. equi vaccine formulation and indicates directions for future research that could potentially improve the efficacy of R. equi vaccines.